{"product_id":"white-light-sr-17-tablets-10ct","title":"White Light - SR-17 Tablets [10ct]","description":"\u003cp\u003e\u003cstrong\u003eWhite Light SR-17\u003c\/strong\u003e is a synthetic G-protein-biased partial agonist of the mu-opioid receptor (MOR), first described by Laura Bohn and colleagues at the Scripps Research Institute in 2017 and patented in 2016. It represents a distinct class of opioid receptor ligands developed to probe the functional consequences of biased MOR signaling.\u003c\/p\u003e\n\n\u003ch3\u003eMechanism of Action\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eG-Protein Biased Agonism\u003c\/strong\u003e — SR-17018 demonstrates strong selectivity for G-protein signaling over β-arrestin2 recruitment at the MOR, with an 80–100 fold bias factor relative to the reference agonist DAMGO.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNon-Competitive Binding Profile\u003c\/strong\u003e — Exhibits non-competitive MOR agonism with nearly irreversible receptor binding characteristics, yet remains fully reversible by antagonists such as naloxone — suggesting allosteric site interaction rather than classical orthosteric binding.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePartial Agonist Efficacy\u003c\/strong\u003e — GTPγS binding: 72–75% efficacy (EC₅₀ 97–193 nM); cAMP accumulation: 105% efficacy (EC₅₀ 76 nM); β-arrestin2 recruitment: ≤10% efficacy (EC₅₀ \u0026gt;10,000 nM).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eReceptor Binding Profile\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMOR Affinity (Kᵢ):\u003c\/strong\u003e 11 nM — high affinity, primary target\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKOR Affinity (Kᵢ):\u003c\/strong\u003e 68 nM — moderate kappa-opioid receptor activity\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDOR Affinity (Kᵢ):\u003c\/strong\u003e \u0026gt;10,000 nM — essentially no delta-opioid receptor activity\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003ePharmacokinetics\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOral Bioavailability:\u003c\/strong\u003e 69% — suitable for oral dosing study designs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCNS Penetration:\u003c\/strong\u003e Efficiently crosses the blood–brain barrier\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eElimination Half-Life:\u003c\/strong\u003e Approximately 6 hours\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLipophilicity:\u003c\/strong\u003e log P = 4.75 (highly lipophilic)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDuration:\u003c\/strong\u003e Longer duration of action than morphine or fentanyl at equivalent doses\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eChemical Data\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₁₉H₁₈Cl₃N₃O\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMolar Mass:\u003c\/strong\u003e 410.72 g·mol⁻¹\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eClass:\u003c\/strong\u003e Piperidinylbenzimidazolone (piperidine-benzimidazole derivative)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e 10ct tablets\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eResearch Context\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTolerance \u0026amp; Withdrawal Research\u003c\/strong\u003e — SR-17018 is studied for its atypical tolerance profile and reduced withdrawal symptom intensity relative to conventional MOR agonists, making it a useful tool compound in opioid dependence research.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOpioid Discontinuation Studies\u003c\/strong\u003e — Investigated as a research tool for understanding opioid tolerance reversal and the pharmacological basis of withdrawal management across opioid classes including fentanyl, heroin, methadone, and buprenorphine.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSafety Pharmacology\u003c\/strong\u003e — Studied for its favorable therapeutic window profile relative to classical opioids, particularly regarding respiratory depression parameters.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eQuality Assurance\u003c\/h3\u003e\n\u003cp\u003eWhite Light research compounds are manufactured under controlled conditions to ensure consistent compound integrity and batch-to-batch reproducibility for reliable research outcomes.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003e⚠ FOR LABORATORY RESEARCH USE ONLY. Not for human consumption. Not FDA-approved. Not a dietary supplement. SR-17018 has not been formally studied in humans and its safety profile in humans is unknown. Handle only by trained research personnel in accordance with applicable institutional protocols.\u003c\/strong\u003e\u003c\/em\u003e\u003c\/p\u003e\n","brand":"White Light","offers":[{"title":"Default Title","offer_id":52474982039733,"sku":null,"price":34.5,"currency_code":"USD","in_stock":false}],"url":"https:\/\/smokeshopdaddy.com\/products\/white-light-sr-17-tablets-10ct","provider":"BLACKMARKET GROUP LLC","version":"1.0","type":"link"}